ArticleNature2026
A µ-opioid receptor superagonist analgesic with minimal adverse effects.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dual-target mu opioid-dopamine DEuropean journal of medicinal chemistry · 2026Article
- Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling.Journal of medicinal chemistry · 2026Article
- Emerging Insights into the Distinct Pharmacological Mechanisms of Buprenorphine.Journal of chemical information and modeling · 2026Article
- Novel opioid provides cleaner pain relief.Nature reviews. Drug discovery · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
44 authors.
Juan L GomezBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Emilya N VentrigliaBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Zachary J FrangosBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5499-4050
Agnieszka SulimaDrug Design and Synthesis Section, Molecular Targets and Medication Discovery Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Michael J RobertsonDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2610-680X
Michael D SaccoDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Reece C BudinichBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Ilinca M GiosanDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Tongzhen XieDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0968-0079
Oscar SolisBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8285-5891
Anna E TischerBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0009-0001-4268-5904
Jennifer M BossertNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Kiera E CaldwellNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Hannah BonbrestNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Amelie EssmannDepartament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0009-0008-9972-8187
Zelai M Garçon-PocaDepartament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-5709-7531
Shinbe ChoiBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0009-0006-3505-4318
Michael R NoyaBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Feonil LimiacBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0009-0000-5180-8948
Ali ArceBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Grant C GlatfelterDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Margaret RobinsonComputational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Li ChenComputational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Angelina A MullarkeyDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Dain R BrademanDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Garrett EntenIntegrative Neurobiology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-9012-0246
William DunneBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0009-0007-1334-6069
César QuirozIntegrative Neurobiology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Ingrid SchoenbornBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0009-0004-4275-9995
Chae Bin LeeJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Daniel P HoltDepartment of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Robert F DannalsDepartment of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lei ShiComputational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4137-096X
Ruth HüttenhainDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1747-1779
Eugene KiyatkinBehavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Jordi BonaventuraDepartament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-4745-0151
Yavin ShahamNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8242-3319
Venetia ZachariouDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Michael H BaumannDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Georgios SkiniotisDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. georgios.skiniotis@stjude.org.ORCID http://orcid.org/0000-0003-0238-7846
Kenner C RiceDrug Design and Synthesis Section, Molecular Targets and Medication Discovery Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. kennerr@nida.nih.gov.ORCID http://orcid.org/0000-0002-1147-9147
Michael MichaelidesBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA. mike.michaelides@nih.gov.ORCID http://orcid.org/0000-0003-0398-4917
Funding
Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptorZIADA000606 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHI, LEI · 2015 to 2025
$20.5MBiobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse MechanismsZIADA000069 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI MICHAELIDES, MICHAEL · 2016 to 2025
$18.9MSpatiotemporal signaling and trafficking of the mu-opioid receptorR01DA056354 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ruth Huttenhain · 2022 to 2026
$2.9MIntramural NIH HHS ZIA DA000069Intramural NIH HHS ZIA DA000606NIDA NIH HHS R01 DA056354
Abstract
Developing safe and effective pain medications is an ongoing challenge for human health. Agonists for the µ-opioid receptor (MOR) are essential pain medications, but their high intrinsic efficacy also induces adverse side effects, including respiratory depression, constipation, tolerance, dependence, withdrawal and addiction
Indexed as
AnalgesicsAnalgesics, OpioidReceptors, Opioid, muAnimalsBenzimidazolesDopamineDrug ToleranceHumansMaleMiceMice, Inbred C57BLNucleus AccumbensPainRatsRats, Sprague-DawleySignal TransductionAnalgesicsAnalgesics, OpioidBenzimidazolesDopamineReceptors, Opioid, mu
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.